

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1/03/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/531,754 (Conf.#6065)
Filing Date	18 April 2005
First Named Inventor	Peter G. KLIMKO
Art Unit	1625
Examiner Name	
Attorney Docket Number	2439 US F

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US- 2002/0037929 A1	03-28-2002	Kapin et al.	
	A2	US- 4,975,537	12-04-1990	Aristoff et al.	
	A3	US- 4,771,042	09-13-1988	Braugher et al.	
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)				
	A20	WO 2004/04352 A2/A3	05-27-2004	Alcon, Inc.		
	A21					
	A22					
	A23					
	A24					
	A25					

Examiner Signature /John Mabry/ (05/06/2008)

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/531,754 (Conf.#6065)
				Filing Date	18 April 2005
				First Named Inventor	Peter G. KLIMKO
				Art Unit	1625
Examiner Name					
Sheet	2	of	3	Attorney Docket Number	2439 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B1	Butler et. al., "Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo," CANCER RESEARCH, 60:5165-5170 (2000)	
	B2	Butler et. al., "Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, and Inhibitor of Histone Deacetylase", CLINICAL CANCER RESEARCH, 7:962-970 (2001)	
	B3	Butler et. al., "The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin", PROC. NATL. ACAD. SCI. USA, 99 (18):11700-11705 (2002)	
	B4	Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment", SCIENCE, 230:1375-1378 (Dec 1985)	
	B5	Deroanne et al., "Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling", ONCOGENE, 21:427-436 (2002)	
	B6	Folkman J and Ingber DE, "Angiostatic Steroids", ANN. SURG., 206(3):374-383 (1987)	
	B7	Ingber, et al., "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution", ENDOCRINOLOGY, 119(4):1768-1775 (1986)	
	B8	International Search Report for PCT/US2003/034617 [2439 WO F]	
	B9	Kelly et al., "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity", PROC. AMER. SOC. CLIN. ONCOL., 20:87a (2001)	
	B10	Kim et. al., "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes", NATURE MEDICINE, 7(4):437-443 (2001)	

Examiner Signature	/John Mabry/ (05/06/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/531,754 (Conf.#6065)
				Filing Date	18 April 2005
				First Named Inventor	Peter G. KLIMKO
				Art Unit	1625
Examiner Name					
Sheet	3	of	3	Attorney Docket Number	2439 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Li, et al., "Angiostatic Steroids Potentiated by Sulphated Cyclodextrin Inhibit Corneal Neovascularization", IOVS, 32(11):2898-2905 (October 1991)	
	C2	Marks et. al., "Histone deacetylase inhibitors as new cancer drugs", CURRENT OPINION IN ONCOLOGY, 13:477-483 (2001)	
	C3	Marks et. al., "Histone Deacetylases And Cancer: Causes And Therapies", NATURE REVIEWS CANCER, 1:194-202 (2001)	
	C4	Mori H et al., "Cyclic tetrapeptide compounds as histone deacetylase inhibitors and their use in therapy", Database CA on STN, Chemical Abstracts, No. 132:288796, WO 2002074298 (Sep 2002)	
	C5	Munster et. al., "The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells", CANCER RESEARCH, 61:8492-8497 (2001)	
	C6	Naka M et al., "Preparation of n-acylaminoalkane-hydroxamic acids as IL-6 production inhibitors", abstract, Database CA on STN, Chemical Abstracts, No. 137:247516	
	C7	Ohno, M. and Otsuka, M., "Chapter 1, Chiral Synthons By Ester Hydrolysis Catalyzed By Pig Liver Esterase", ORGANIC REACTIONS, 37:1-55 (1989)	
	C8	Suzuki et al., "Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives", J. MED. CHEM., 42(15):3001-3003 (1999)	
	C9	Timmermann S et al., "Histone acetylation and disease", CELLULAR AND MOLECULAR LIFE SCIENCES, 58:728-736 (2001)	
	C10		

Examiner Signature	/John Mabry/ (05/06/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./